Clinical review: Impact of statin substitution policies on patient outcomes

Dan Atar*, Rafael Carmena, Peter Clemmensen, Annik K-Laflamme, Sven Wassmann, Peter Lansberg, Richard Hobbs

*Corresponding author for this work

    Research output: Contribution to journalReviewResearchpeer-review


    Background. The increasing awareness of cost issues in health care has led to the increasing use of policy-driven substitution of branded for generic medications, particularly relative to statin treatment for cardiovascular diseases. While there are potential short-term health care savings, the consequences for primary care are under-researched. Our objective was to review data on intensive statin therapy and generic substitution in patients at high cardiovascular risk. Results. Current treatment guidelines for the prevention of cardiovascular disease are consistent in their recommendations regarding statin therapy and treatment targets. Clinical trials demonstrate that to reduce cardiovascular events, a statin is more effective than placebo, intensive statin therapy is more effective than moderate statin therapy in patients with established coronary disease, and in patients receiving intensive statin therapy the lowest risk is associated with the lowest low-density lipoprotein levels. However, in clinical practice, patients at high cardiovascular risk are prone to be undertreated. Observational studies suggest that mandatory statin substitution may increase the gap between achieved and recommended therapeutic targets. Conclusions. Substitution of generic statins may be cost-saving, particularly at the primary prevention level. However, statin substitution policies have not been adequately studied on a population level. Data raise concern that mandated statin substitution may lead to unfavourable treatment choices at the level of the individual high-risk patient.

    Original languageEnglish
    Pages (from-to)242-256
    Number of pages15
    JournalAnnals of Medicine
    Issue number4
    Publication statusPublished - 4 Nov 2009


    • Cardiovascular disease
    • Cholesterol
    • Cost-effectiveness
    • Low-density lipoprotein
    • Policy
    • Statin
    • Substitution
    • Switching


    Explore the research areas of 'Clinical review: Impact of statin substitution policies on patient outcomes'.

    Cite this